IL286767A - Preparations and methods of their use for the treatment of neurodegenerative and mitochondrial diseases - Google Patents

Preparations and methods of their use for the treatment of neurodegenerative and mitochondrial diseases

Info

Publication number
IL286767A
IL286767A IL286767A IL28676721A IL286767A IL 286767 A IL286767 A IL 286767A IL 286767 A IL286767 A IL 286767A IL 28676721 A IL28676721 A IL 28676721A IL 286767 A IL286767 A IL 286767A
Authority
IL
Israel
Prior art keywords
neurodegenerative
compositions
treatment
methods
same
Prior art date
Application number
IL286767A
Other languages
English (en)
Hebrew (he)
Original Assignee
Mitokinin Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitokinin Inc filed Critical Mitokinin Inc
Publication of IL286767A publication Critical patent/IL286767A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL286767A 2019-04-03 2021-09-29 Preparations and methods of their use for the treatment of neurodegenerative and mitochondrial diseases IL286767A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962828995P 2019-04-03 2019-04-03
US201962879794P 2019-07-29 2019-07-29
US201962933632P 2019-11-11 2019-11-11
PCT/US2020/026732 WO2020206363A1 (en) 2019-04-03 2020-04-03 Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease

Publications (1)

Publication Number Publication Date
IL286767A true IL286767A (en) 2021-12-01

Family

ID=72666280

Family Applications (1)

Application Number Title Priority Date Filing Date
IL286767A IL286767A (en) 2019-04-03 2021-09-29 Preparations and methods of their use for the treatment of neurodegenerative and mitochondrial diseases

Country Status (11)

Country Link
US (2) US20220162215A1 (enExample)
EP (1) EP3947390A4 (enExample)
JP (1) JP2022527025A (enExample)
KR (1) KR20220004068A (enExample)
CN (1) CN114026093A (enExample)
AU (1) AU2020253561A1 (enExample)
BR (1) BR112021019802A2 (enExample)
CA (1) CA3135755A1 (enExample)
IL (1) IL286767A (enExample)
MX (1) MX2021012129A (enExample)
WO (1) WO2020206363A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018237145A1 (en) 2017-06-21 2018-12-27 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
WO2023023671A1 (en) * 2021-08-20 2023-02-23 Mitokinin, Inc. Compositions and methods for treatment of neurodegenerative and mitochondrial disease
WO2023023670A1 (en) * 2021-08-20 2023-02-23 Mitokinin, Inc. Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
WO2024040266A2 (en) * 2022-08-19 2024-02-22 Mitokinin, Inc. Disubstituted benzoimidazole and indole analogs as modulators of pink1
EP4620957A1 (en) * 2024-03-22 2025-09-24 Eberhard Karls Universität Tübingen Imidazo[4,5-b]pyridin-7-amine compounds binding aurora kinase a and uses thereof
CN118290348A (zh) * 2024-03-22 2024-07-05 诚达药业股份有限公司 一种4-氯吡咯并嘧啶类化合物或其衍生物的合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9613021D0 (en) * 1996-06-21 1996-08-28 Pharmacia Spa Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
CN101316853B (zh) * 2005-08-04 2014-09-24 西特里斯药业公司 作为sirtuin调节剂的苯并噻唑和噻唑并吡啶
ES2412384T3 (es) * 2006-07-18 2013-07-11 Astellas Pharma Inc. Derivado de aminoindano o sal del mismo
AU2014214561C1 (en) * 2013-02-11 2019-01-17 Mitokinin, Inc. Compositions and methods for treating neurodegenerative diseases
EP2818472A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators
ES2919024T3 (es) * 2014-02-11 2022-07-21 Mitokinin Inc Composiciones y procedimientos que utilizan las mismas para el tratamiento de enfermedades neurodegenerativas y mitocondriales
CN108934162A (zh) * 2015-12-16 2018-12-04 南方研究所 吡咯并嘧啶化合物、作为激酶lrrk2抑制剂的用途及其制备方法
WO2018065365A1 (en) * 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
WO2018106818A1 (en) * 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
WO2018237145A1 (en) * 2017-06-21 2018-12-27 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
KR20220158290A (ko) * 2020-02-21 2022-11-30 미토키닌, 인크. 신경퇴행성 및 미토콘드리아 질환의 치료를 위한 조성물 및 이를 사용하는 방법

Also Published As

Publication number Publication date
WO2020206363A1 (en) 2020-10-08
EP3947390A1 (en) 2022-02-09
MX2021012129A (es) 2022-01-31
US20220162215A1 (en) 2022-05-26
CN114026093A (zh) 2022-02-08
KR20220004068A (ko) 2022-01-11
CA3135755A1 (en) 2020-10-08
AU2020253561A1 (en) 2021-12-02
US20250250276A1 (en) 2025-08-07
JP2022527025A (ja) 2022-05-27
EP3947390A4 (en) 2022-11-30
BR112021019802A2 (pt) 2021-12-07

Similar Documents

Publication Publication Date Title
IL298689B1 (en) Preparations and methods for suppressing masp-3 for the treatment of various diseases and conditions
ZA202004025B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
IL280710A (en) Methods and compositions for treating mitochondrial disease or disorders and heteroplasmy
ZA202002166B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
IL279397A (en) New compounds and their pharmaceutical preparations for the treatment of diseases
ZA202006610B (en) Compositions for the treatment of skin conditions
ZA202007055B (en) Compositions for the treatment of skin conditions
ZA202006234B (en) Compositions and methods for the treatment of neurological diseases
IL274588A (en) Methods and preparations for improving lysosome function and treating neurodegenerative disease
HUE073261T2 (hu) Készítmények fehérje-aggregációs betegségek kezelésére és/vagy megelõzésére
IL272937A (en) Preparations and methods for the treatment of diseases involving fibrosis
IL326926A (en) Compositions and methods of use thereof for treating neurodegenerative and mitochondrial diseases
GB201702603D0 (en) Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
SG11202103070VA (en) Donecopride as neuroprotective agent in the treatment of neurodegenerative diseases
EP3672583A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES
IL280262A (en) Compositions and methods for treating cancer
IL276228A (en) Compounds and preparations for the treatment of pain
HK40067779A (en) Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
GB201814764D0 (en) Pharmaceutical compositions for the treatment of proteinopathies
GB201817344D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
GB201817343D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
GB201720101D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
GB201809836D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
HK40009011A (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
AU2017901730A0 (en) Compositions for the Treatment of Diseases and Conditions